DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Diiodohydroxyquin (iodoquinol),
1153t
cream, 1153t
Diisopropyl phosphorofluoridate
(DFP), 242
DILACOR XR (diltiazem), 762t, 831
DILATRATE-SR (isosorbide dinitrate),
754t
Dilitiazem
ABC transporters and, 105t
pharmacokinetics of, 1832t
Diloxanide furoate, 1424
Diltiazem, 761
absorption, fate, and excretion of,
765
antiarrhythmic use of, 830, 831,
835t
as antihypertensive agent, 774t
arrhythmias caused by, 821t
cardiovascular pharmacology of,
762t
contraindications to, 833t
digoxin and, 839
dosage of, 835t
electrophysiological actions of, 829t
hemodynamic effects of, 765
pharmacokinetics of, 835t
pharmacology of, 764, 765
structure of, 762t
therapeutic uses of, 767
for angina, 766
Dimaprit, 912, 912f, 916
Dimenhydrinate, 921t
therapeutic uses of, 923
Dimercaprol, 1874
as antidote, 86t
Dimercaptopropane sulfonate (DMPS),
1874–1875
Dimerization, receptor, 55
Dimethylphenylpiperazinium (DMPP),
211
Dinoprostone
for cervical ripening, 952,
1849–1850
for pregnancy termination, 1837
DIOVAN (valsartan), 738
Diphenhydramine, 918, 921t, 923,
1816
as antidote, 86t
arrhythmias caused by, 832
pharmacokinetics of, 1816t, 1832t
structure of, 919f
therapeutic uses of, as antinausea
agent, in cancer
chemotherapy, 1344t
Diphenoxylate, 507, 1338
structure of, 504f
Diphenylmethane derivatives, 1333
effects on bowel function, 1330t
Diphtheria, penicillin for, 1487
Diphyllobothrium latum, 1448
Dipifevrin, for ophthalmic use, 1787
Diplopia, 1788
botulinum toxin and, 1792
Diprenorphine, actions and
selectivities, 485t
DIPROLENE (betamethasone
dipropionate cream), 1225t
DIPROSONE (betamethasone
dipropionate), 1225t
Dipyridamole, 103t, 755
drug interactions with, 834
Dipyrone, 138t, 990
Direct-to-consumer (DTC) advertising,
1883
Discoid lupus erythematosus, retinoids
for, 1811
Disease-modifying antirheumatic
drugs, 965, 993–994, 994t
Disequilibrium, linkage, 149
Disopyramide
adverse effects of, 839
antiarrhythmic use of, 835t, 839
arrhythmias caused by, 821t
contraindications to, 833t
dosage of, 835t
electrophysiological actions of, 829t
pharmacokinetics of, 835t, 839
pharmacology of, 839
structure of, 839
Dispositional antagonism, 78
Disposition of drugs, 28
anticholinesterases, 249
Distal convoluted tubule, 673
Distribution of drugs, 23–25, 30–38
ABC transporters in, 105t–106t
absorption and, 18f
binding and, 18f
bone and, 24–25
central nervous system and, 25
cerebrospinal fluid and, 25
excretion and, 18f
factors affecting, 23
fat and, 24
ganglionic blocking, 273–274
metabolism and, 18f
neuromuscular blocking agents, 263
nicotine, 271–272
pH and, 18–19, 23–24
plasma binding and, 24
Distribution of drugs (Cont.):
plasma proteins and, 24
rate of, 30–31
redistribution, 25
steady-state, 32
tissue binding and, 24–25
volume of, 30–32, 1804
alteration for individual patients,
1807
of common drugs, 1809t–1890t
disposition and, 28
as pharmacodynamic parameter,
1804
Disulfiram, for alcoholism, 643–644
Diuresis, ethanol and, 637
Diuretics, 677–701. See also Carbonic
anhydrase inhibitors
action, principles of, 677
adverse effects and side effects of,
701
antagonists of mineralocorticoid
receptors, 678t, 692–695
absorption and elimination of,
694
drug interactions with, 694–695
mechanism of action of,
692–693
pharmacology of, 693t
and renal hemodynamics, 694
site of action of, 692–693
structure of, 693t
therapeutic uses of, 695
toxicity, adverse effects, and
contraindications to,
694–695
and urinary excretion, 693–694
as antihypertensive agents, 774t,
775–778
clinical uses of, 696–701
dosage and administration of,
699–701
drug interactions with, 778, 839
effects on renin-angiotensin system,
746t
for heart failure, 790–793
in clinical practice, 791–792
in decompensated patient, 792
metabolic consequences, 792
resistance, 792, 793t
hemodynamic effects of, with longterm
administration, 774t
high-ceiling, 682–686, 683t
excretory and renal hemodynamic
effects of, 678t
hyperglycemia and, 1248t
2019
INDEX